Stryker Stock Drops 7.7% on Persistent Manufacturing, Demand Headwinds

Shares of Stryker Corp. (NYSE: SYK) fell as much as 7.7% on Tuesday after company executives signaled that operational challenges are proving more persistent than previously anticipated.

Speaking at the Wells Fargo Healthcare Conference, Chief Financial Officer Preston Wells provided an update on ongoing issues in the company's peripheral vascular and joint replacement businesses, leading to a negative reaction from investors.

Extended Supply Chain Disruptions

A key concern is a manufacturing problem that has constrained Stryker's ability to maintain a full inventory supply for its peripheral vascular customers. Wells confirmed this issue not only limits current sales but also hinders the company's capacity to pursue new business opportunities.

While the company had previously expected to resolve the problem in the third quarter, the timeline has now been extended. "What we’re seeing is that is continuing into the third quarter. We expect it to continue a little bit into the fourth quarter as well," Wells stated at the conference.

Weaker Joint Replacement Recovery

Ad

Stryker also reported weaker-than-anticipated performance in its joint replacement division. Following a strong June, the company had expected a continued recovery through the summer months.

Instead, the business experienced more typical seasonal slowdowns. "We actually did not see the recovery that we expected so far in the quarter, although we are anticipating to have a better September," Wells said, adjusting expectations for the unit's performance.

Market Impact

The updated guidance sent a chill through the medical technology sector. In addition to Stryker's significant single-day drop, shares of peer company Zimmer Biomet (NYSE: ZBH) also declined on the news, reflecting broader investor concern about headwinds in the industry.